NASDAQ:BGNE - Beigene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $121.11 +0.84 (+0.70 %) (As of 04/23/2019 04:00 PM ET)Previous Close$120.27Today's Range$117.67 - $121.8352-Week Range$105.19 - $220.10Volume571,143 shsAverage Volume357,595 shsMarket Capitalization$7.23 billionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia. The company's clinical stage drug candidates include BGB-3111, a small molecule Bruton's tyrosine kinase (BTK) inhibitor for the treatment of lymphomas; BGB-A317, a humanized monoclonal antibody for solid and hematological cancers; and BGB-290, a small molecule inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers. In addition, its clinical stage drugs include BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway; BGB-A333, a humanized monoclonal antibody for the immune checkpoint receptor ligand PD-L1; BGB-A425, a TIM-3 inhibitor; MGCD-0516, a multi-kinase inhibitor; and CC-122, a cereblon modulator. The company has collaborations with Celgene Corporation, Merck KGaA, Mirati Therapeutics, Inc., Zymeworks, and Ambrx, Inc. BeiGene, Ltd. was founded in 2010 and is based in George Town, the Cayman Islands. Receive BGNE News and Ratings via Email Sign-up to receive the latest news and ratings for BGNE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BGNE Previous Symbol CUSIPN/A CIK1651308 Webwww.beigene.com Phone1-345-949-4123Debt Debt-to-Equity Ratio0.11 Current Ratio7.89 Quick Ratio7.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$198.22 million Price / Sales36.48 Cash FlowN/A Price / Cash FlowN/A Book Value$29.52 per share Price / Book4.10Profitability EPS (Most Recent Fiscal Year)($12.15) Net Income$-673,770,000.00 Net Margins-339.91% Return on Equity-42.63% Return on Assets-33.60%Miscellaneous Employees2,070 Outstanding Shares59,713,000Market Cap$7.23 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Beigene (NASDAQ:BGNE) Frequently Asked Questions What is Beigene's stock symbol? Beigene trades on the NASDAQ under the ticker symbol "BGNE." How were Beigene's earnings last quarter? Beigene Ltd (NASDAQ:BGNE) released its quarterly earnings results on Wednesday, February, 27th. The company reported ($4.52) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($2.87) by $1.65. The business had revenue of $58.67 million for the quarter, compared to the consensus estimate of $59.37 million. Beigene had a negative net margin of 339.91% and a negative return on equity of 42.63%. Beigene's revenue was up 222.8% on a year-over-year basis. During the same period in the previous year, the business posted ($2.19) EPS. View Beigene's Earnings History. When is Beigene's next earnings date? Beigene is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Beigene. What price target have analysts set for BGNE? 9 analysts have issued 12-month price objectives for Beigene's stock. Their predictions range from $160.75 to $215.00. On average, they anticipate Beigene's stock price to reach $181.6250 in the next twelve months. This suggests a possible upside of 50.0% from the stock's current price. View Analyst Price Targets for Beigene. What is the consensus analysts' recommendation for Beigene? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beigene in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beigene. What are Wall Street analysts saying about Beigene stock? Here are some recent quotes from research analysts about Beigene stock: 1. According to Zacks Investment Research, "BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands. " (3/4/2019) 2. Maxim Group analysts commented, "This morning, Bristol-Myers Squibb (BMY – NR) announced it will acquire Celgene (CELG – NR) for ~$74B, projected to close 3Q19. BGNE shares were initially down ~30% but have climbed back to being down only ~10%. The pressure on the stock is due to the questions around the CELG/BGNE partnership for PD1, tislelizumab. There are two scenarios we see that can play out for BGNE, assuming the transaction closes: 1. BMY ends the partnership with BGNE: Most likely, in our view as BMY has Opdivo which generates ~$5B globally (and has its first approval in China). BMY can take back Revlimid in China, also likely. The positives for BGNE: ○ BGNE regains global rights to tislelizumab which is now in 10 ongoing pivotal trials, is closer to approval(s) and positions the company to get an even better deal than it got with CELG." (1/3/2019) Has Beigene been receiving favorable news coverage? Media headlines about BGNE stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Beigene earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. Who are some of Beigene's key competitors? Some companies that are related to Beigene include ASTELLAS PHARMA/ADR (ALPMY), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Marina Biotech (MRNA), Bausch Health Companies (BHC), SAGE Therapeutics (SAGE) and Jazz Pharmaceuticals (JAZZ). What other stocks do shareholders of Beigene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Beigene investors own include Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Celgene (CELG), Adobe (ADBE), Amgen (AMGN), Biogen (BIIB), Crispr Therapeutics (CRSP) and GW Pharmaceuticals PLC- (GWPH). Who are Beigene's key executives? Beigene's management team includes the folowing people: Mr. John V. Oyler, Co-Founder, CEO & Chairman (Age 51)Dr. Xiaodong Wang, Co-Founder, Chairman of the Scientific Advisory Board & Director (Age 56)Dr. Heng Liang, CFO & Chief Strategy Officer (Age 56)Dr. Jane E. Huang M.D., Chief Medical Officer - Hematology (Age 46)Dr. Xiaobin Wu, Pres & Gen. Mang. of China When did Beigene IPO? (BGNE) raised $126 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager. Who are Beigene's major shareholders? Beigene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Brinker Capital Inc. (0.01%). Company insiders that own Beigene stock include Amy C Peterson, Bros Advisors Lp Baker, Donald W Glazer, Howard Liang, Jane Huang, Ji Li, John Oyler and Xiaodong Wang. View Institutional Ownership Trends for Beigene. Which institutional investors are buying Beigene stock? BGNE stock was bought by a variety of institutional investors in the last quarter, including Brinker Capital Inc.. View Insider Buying and Selling for Beigene. How do I buy shares of Beigene? Shares of BGNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Beigene's stock price today? One share of BGNE stock can currently be purchased for approximately $121.11. How big of a company is Beigene? Beigene has a market capitalization of $7.23 billion and generates $198.22 million in revenue each year. The company earns $-673,770,000.00 in net income (profit) each year or ($12.15) on an earnings per share basis. Beigene employs 2,070 workers across the globe. What is Beigene's official website? The official website for Beigene is http://www.beigene.com. How can I contact Beigene? Beigene's mailing address is 94 SOLARIS AVENUE CAMANA BAY, GRAND CAYMAN E9, KY1-1108. The company can be reached via phone at 1-345-949-4123 or via email at [email protected] MarketBeat Community Rating for Beigene (NASDAQ BGNE)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 364 (Vote Outperform)Underperform Votes: 296 (Vote Underperform)Total Votes: 660MarketBeat's community ratings are surveys of what our community members think about Beigene and other stocks. Vote "Outperform" if you believe BGNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGNE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/23/2019 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?